linkage
Some good job relocation news
Some good job relocation news
In the Brussels Report of the April issue of Pharmaceutical Technology Europe,1 Albedo stated that despite of the European Union's (EU's) wish to keep pharmaceutical and biotechnology development moving in the right direction, things are not going according to plan. This is hardly surprising given that the EU's answer to most problems in the industry is to write another piece of legislation. However, this only achieves the opposite effect and forces EU companies to relocate - mainly to the US.
Indications during the last 5 years suggest that many of the big pharmaceutical companies have moved their research and development (R&D) units to the US, leaving Europe with mainly small-sized companies.2 No reasons have been provided for the moves, but the US must offer something that Europe does not. This article briefly considers the possible reasons why large pharmaceutical companies are relocating from Europe to the US.
Europe is not short of highly qualified scientists and salaries are not significantly different compared with the US.3 The market size of both is similar, although Europe will perhaps has a slight advantage after enlagement in 2004. Prices paid by health servers and insurance companies in Europe are lower than in the US, making Europe less profitable to big pharmaceutical companies. Perhaps relocation is being caused by regulations.